| Name | Title | Contact Details |
|---|
ShopperTrak is the leading global provider of shopper insights and analytics that enable retailers to improve profitability and effectiveness. As the retail industry’s premier provider of actionable retail insights, more than 1,000 of the world’s leading retail brands, shopping center owner/operators and entertainment venues have ShopperTrak services deployed in over 70,000 locations across more than 90 countries and territories. Headquartered in Chicago, we employ more than 200 individuals and maintains offices in: San Francisco, USA; Dubai, United Arab Emirates; Helsinki, Finland; High Wycombe, England; Mexico City, Mexico; and Shenzhen, China.
We are a premium equity and stock option idea chatroom based on advanced technical analysis. We generate actionable and profitable trade ideas in real time among a group of seasoned international traders and guide members with educational mate...
General Micro Systems Inc is a Rancho Cucamonga, CA-based company in the Business Services sector.
Sustainable Harvest Coffee Importers is a Portland, OR-based company in the Business Services sector.
Apellis Pharmaceuticals is a global biopharmaceutical company based in Waltham, Massachusetts. The company is focused on developing innovative therapies that target the complement system, a crucial part of the immune system. Apellis aims to create life-changing treatments for various debilitating diseases through its commitment to scientific research and patient care. The company has a diverse pipeline of products, including EMPAVELI, which is approved for treating paroxysmal nocturnal hemoglobinuria and is being investigated for other conditions. SYFOVRE is in development for geographic atrophy, along with a combination therapy involving APL-APL-3007. Apellis is also exploring RNA therapies and gene-edited treatments for multiple therapeutic areas. With a global presence in countries such as the US, Canada, and several European nations, Apellis serves patients and healthcare providers affected by diseases related to the complement system. The company reported approximately $709 million in U.S. net product revenues for the full year 2024, reflecting its strong market position and commitment to advancing its therapeutic offerings.